🧵 1/9
Elderly male. Metastatic colorectal cancer with liver mets. RAS wild-type — looks straightforward.
Then the molecular profile comes back: HER2 IHC 3+.
This changes the entire treatment plan. Here's why 👇
8/9
Key detail on testing 🔬
IHC 3+ responds well. IHC 2+ without amplification — almost no benefit.
Use HERACLES criteria, not breast cancer scoring. And when possible, test the metastatic tissue — not just the primary.
9/9
The takeaway:
🔵 HER2 3+ rules out anti-EGFR therapy
🔵 Opens access to two approved targeted regimens
🔵 Age is not a reason to treat blind
Test it, it really matters.
#gipath #pathtwitter #pathology
Anna Vasileva retweeted
Hard time remembering all those #hemepath immunostains/markers? This chart by Dr. Jeanette Ramos will help! Full chart free here: kikoxp.com/posts/20554.
#medstudents #pathTwitter #path2path #usmle #MedStudentTwitter #MedED #medtwitter #hematology #hemeonc #lymphoma #leukemia
🧵 1/6
A nodule on the face. Sent as a skin biopsy. No clinical history provided. Spoiler: this is NOT a primary skin tumor. 👇
#pathtwitter #dermpath #uropath #pathology
5/6
📌 Take-home points:
— Clear cells in skin = always rule out metastasis
— RCC loves to metastasize late and to unusual sites
— PAX8 + CD10 + CAIX = your best IHC friends here
Anna Vasileva retweeted
1/3 #GIpath #CritterOnTwitter Look what I found in this inflamed antral hyperplastic gastric polyp 🤓. At first glance, I thought that it is hallucinations or illusions due to end of the week fatigue 😂 then I started to take images of every single one. So all are represented 😅
Anna Vasileva retweeted
#PathQuiz 🔬🦋 #ThyroidPath
A) NIFTP
B) High-grade follicular cell-derived thyroid carcinoma
C) Oncocytic Carcinoma
D) Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
#Pathology #ThyroidPath
Anna Vasileva retweeted
ADH in Radial Scar 🫚🔬
Occasionally, atypia can be spotted within sclerosing lesions—here, a monotonous epithelial proliferation partially filling ducts within a fibroelastotic, architecturally distorted background.
#PathX #PathTwitter #breastpath
🧵 Not all breast carcinomas are created equal 🧬
Here's how p63 expression shifts as tumors progress toward a basal/stem-cell phenotype👇
#pathtwitter #breastpath #pathology

ALT Illustrated diagram showing p63 expression across three breast tumor types. Tumor 1 (G1/G2 NST): uniformly blue cells, p63-negative. Tumor 2 (G3 NST): predominantly blue cells with scattered brown cells, p63-positive, triggered by TP53 mutation. Tumor 3 (Metaplastic carcinoma): predominantly brown cells, p63-strongly positive. An arrow along the bottom indicates increasing basal program activation, aggressiveness, and stem-cell phenotype from left to right.



















